Global Alopecia Treatment (Hair Loss) Market is expected to grow with the CAGR of 6.0% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.
Global alopecia treatment (hair loss) market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in global alopecia treatment (hair loss) market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the alopecia treatment (hair loss) market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in March 2018, Johnson & Johnson Services, Inc. teamed up with JW Pharmaceutical. The company has taken this decision in order to enhance the sales of Rogaine, a hair loss treatment containing minoxidil. Rogaine is a FDA approved alopecia treatment and is one of the top selling hair loss treatment brands. This initiative has helped the company to enhance the company’s overall revenue.
Johnson & Johnson Services, Inc. is the dominating player in global alopecia treatment (hair loss) market. The other key players existing in the alopecia treatment (hair loss) market are Alès Groupe, Gerolymatos International SA, iGrow Laser, Lexington Intl., LLC., Curallux, LLC., Follicum AB, HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, Vitabiotics Ltd., WOCKHARDT, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), Pfizer Inc., Par Pharmaceutical (a subsidiary of Endo International plc), GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Aurobindo Pharma, Perrigo Company plc, Viviscal Limited (a subsidiary of Church & Dwight Co., Inc.), Dr. Kurt Wolff GmbH & Co. KG, Nanogen, Labo International S.r.l., Watermans, WON TECH Co., Ltd., PureTech among others.
Johnson & Johnson Services, Inc. is headquartered in New Jersey, U.S. and was founded in 1886. The company is focused on improving access and affordability, create healthier communities and put a healthy mind, body and environment within reach of everyone, everywhere. The company has three business segments including consumer, pharmaceutical and medical devices in which consumer is the market focused segment. The company has wide range of products under categories such as consumer health products, medical devices and pharmaceutical products in which consumer health products is the market focused category.
The company has wide presence across Asia, Europe, America and Middle East and Africa. The company also has various subsidiary companies such as Janssen Pharmaceutica (Belgium), Neutrogena (U.S.), DePuy Synthes Companies (U.S.), Ethicon Inc. (U.S.), ALZA Corporation (U.S.) among others.
GlaxoSmithKline plc is headquartered in Ontario, Canada and was founded in 1715. The company is focused on bringing differentiated, high quality and needed healthcare products to as many people as possible with its three global businesses, scientific and technical know- how and talented people. The company operates its business through three business segments which are pharmaceuticals, vaccines and consumer healthcare in which pharmaceuticals is the market focused segment. The company has wide range of products under categories such as our prescription medicines, our vaccines, our consumer healthcare products, ViV Healthcare and stiefel- dermatology in which our prescription medicines is the market focused category.
The company has presence across Africa, Asia & Middle East, Australasia, Europe, North America, South and Central America. The company has various subsidiaries such as 1506369 Alberta ULC (Canada), Action Potential Venture Capital Limited (England), Adechsa GmbH (Switzerland), Alenfarma – Especialidades Farmaceuticas, Limitada (Portugal), Allen & Hanburys Pharmaceutical Nigeria Limited (Nigeria) among others.
Taisho Pharmaceutical Holdings Co., Ltd.:
Taisho Pharmaceutical Holdings Co., Ltd. Is headquartered in Tokyo, Japan and was founded in 1912. The company is focused on manufacturing of OTC brands with a thought to improve patients’ health as its specialty. The company operates its business through two business segments which are self-medication operation group and prescription pharmaceutical operation group in which self-medication operation group is the market focused segment. The company has various products under categories that are lipovitan series, pabron series, RiUP series, counterpain, tempra, hapacol, dafalgan and efferalgan in which RiUP series is the market focused category.
The company has presence in the Americas, Europe and Asia. The company also has various subsidiaries that are Taisho Pharmaceutical California Inc. (U.S.), Taisho Pharmaceutical (Taiwan) Co., Ltd (Taiwan), Grupo Imperial, S.A. de C.V. (Japan), Taisho Pharmaceutical (m) Sdn Bhd (Malaysia), PT Taisho Pharmaceutical Indonesia Tbk (Indonesia) among others.
Global Alopecia Treatment (Hair Loss) Market – Industry Trends and Forecast to 2028
Asia-Pacific Alopecia Treatment (Hair Loss) Market – Industry Trends and Forecast to 2027
Europe Alopecia Treatment (Hair Loss) Market – Industry Trends and Forecast to 2027
Middle East and Africa Alopecia Treatment (Hair Loss) Market – Industry Trends and Forecast to 2027
North America Alopecia Treatment (Hair Loss) Market – Industry Trends and Forecast to 2027